CTOs on the Move

Lyndra

www.lyndra.com

 
Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company`s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra`s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.lyndra.com
  • 65 Grove Street Suite 301
    Watertown, MA USA 02472
  • Phone: 857.201.5314

Executives

Name Title Contact Details
Jacqueline Fernandes
 Vice President of Data Compliance and Information Technology Profile
Kyle Haraldsen
 Chief Technology Officer Profile
Orn Almarsson
 Chief Technology Officer Profile

Funding

Lyndra raised $23M on 04/13/2017
Lyndra raised $55M on 01/29/2019
Lyndra raised $13M on 07/30/2019

Similar Companies

Antibacterial Resistance Leadership Group (ARLG)

ARLG addresses antibacterial resistance through innovative clinical trial design, unique access to clinically well-characterized bacteria, and opportunities for early-stage investigators.

Yumanity

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the fact that an estimated 50 million people worldwide suffer from diseases affecting the brain and central nervous system, there are no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs, including Alzheimer`s disease, Parkinson`s disease and amyotrophic lateral sclerosis (ALS). The company`s approach concentrates on correcting the cellular pathologies driven by misfolded proteins, the altered biology or phenotypes driving these diseases. Yumanity Therapeutics was founded in December 2014 by Susan Lindquist, Ph.D., award-winning protein folding expert, and Tony Coles, M.D., a renowned biotech industry leader. The company`s proprietary platforms have already identified one potential new target for treating Parkinson`s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer`s disease and ALS. Targeting the underlying protein pathology of neurodegenerative diseases allows the company to discover therapies that may modify the root cause of these rather than only addressing their symptoms.

LifeServe Blood Center

LifeServe Blood Center is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kyverna Therapeutics

Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases. Our therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of disease. Kyverna is venture-backed and located in the San Francisco East Bay.

Scientific Specialties

Leading innovator in Life Science Laboratory Consumables: Pipette Tips; PCR; Screw Cap, Centrifuge, and Cryogenic Tubes; HTS; and Tubes Racks.